Ocular Therapeutix (OCUL) Share-based Compensation (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Share-based Compensation of $105025.0 for Q2 2026, down 99.89% year-over-year from $91.9 million in Q2 2025, and down 99.91% on a QoQ basis from $115.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Share-based Compensation (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Share-based Compensation for 14 years, with the latest figure at $105025.0 in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $105025.0, down 99.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $105025.0 (down 99.89% YoY), and the FY2025 annual result was $79.4 million, up 47.6% from the prior year.
- Share-based Compensation slipped to $105025.0 in Q2 2026, from $115.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $115.2 million in Q1 2026 and troughed at $105025.0 in Q2 2026.
- A 5-year average of $25.1 million and a median of $5.9 million in 2023 frame the typical range for Share-based Compensation.
- The largest YoY upside for Share-based Compensation was 1001.52% in 2026 against a maximum downside of 99.89% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $4.2 million in 2022, then grew by 2.22% to $4.3 million in 2023, then jumped by 66.29% to $7.2 million in 2024, then jumped by 57.83% to $11.4 million in 2025, then slumped by 99.08% to $105025.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $105025.0 in Q2 2026, $115.2 million in Q1 2026, and $11.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 105,025.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105,025.00 |
| Jun 30, 2026 | 105,025.00 |
| Mar 31, 2026 | 2.51 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Dec 31, 2025 | 11.36 Mn |
| Dec 31, 2025 | 11.36 Mn |
| Sep 30, 2025 | 84.67 Mn |
| Sep 30, 2025 | 84.67 Mn |
| Jun 30, 2025 | 91.91 Mn |
| Jun 30, 2025 | 91.91 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 43.73 Mn |
| Jun 30, 2024 | 43.73 Mn |
| Mar 31, 2024 | 7.98 Mn |
| Mar 31, 2024 | 7.98 Mn |